In the world of diabetes management, a revolution has taken place, offering hope and convenience to those living with this chronic condition. However, as we delve deeper into the story of Tye Cummins and his experience with an insulin pump, a darker side emerges, raising crucial questions about the balance between technological advancement and patient safety.
The Promise of Diabetes Technology
Diabetes treatment has come a long way from the traditional finger-prick tests and insulin injections. Automated insulin pumps and continuous glucose monitors (CGMs) have transformed the lives of many, providing real-time data and automated insulin delivery. Dr. Ashley Ng, a leading diabetes educator, emphasizes the life-changing impact of these devices, backed by high-quality evidence showcasing improved blood sugar control and reduced complications.
The Dark Side: Adverse Events and Regulatory Concerns
Despite the promise, a shadow looms over these technological advancements. The Therapeutic Goods Administration (TGA) tracks adverse event reports, revealing a startling trend: diabetes management devices top the list of devices with the most reported issues. The TGA's database, while public, lacks aggregate data, making it challenging for consumers to identify problematic devices.
An investigation by this masthead uncovered a disturbing reality: diabetes devices account for seven of the top ten devices with adverse event reports since 2024, and five of the top ten spots for injury or death reports. This highlights a critical tension between technological progress and the adequacy of warnings and regulations.
Accuracy and Alarm Failures: A Deadly Combination
Many complaints focus on accuracy issues, alarm failures, and connectivity problems. While the TGA emphasizes that adverse event reports do not necessarily implicate the device, diabetes experts are concerned. They believe the TGA has relaxed regulatory requirements for monitors, allowing less accurate devices onto the market.
The potential for Bluetooth connections to mute crucial blood sugar alarms, as warned by US regulators, is a significant concern. A Victorian coronial inquest is investigating a high-profile car crash that may be linked to a CGM's failure to raise an alarm due to a Bluetooth issue, resulting in five deaths.
Government-Subsidized Devices and Their Issues
The Omnipod 5 insulin pump, partially subsidized by the federal government, is associated with a significant number of adverse event reports, including injuries and cases of hyperglycemia. Hundreds of deaths related to insulin pumps have been reported in the US, and some batches of the Omnipod 5 were recently recalled in Australia due to an insulin leaking issue.
The government-subsidized glucose monitors from Dexcom, Abbott, and MiniMed are also linked to adverse event reports, including injuries and, in one case, a death. While the device manufacturers attribute the number of incidents to the large user base, concerns about accuracy and reliability persist.
Inaccurate Measurements and Their Impact
Interviews with individuals living with diabetes reveal highly inaccurate CGM measurements compared to finger-prick tests. Diabetes educator Bec Ritchie confirms that inaccuracy is a common issue, especially when CGMs are connected to insulin pumps, leading to over or under-insulin delivery and potentially dangerous hypo or hyperglycemia.
Yvette Petrie, who manages her type 1 diabetes with a CGM and automatic insulin pump, shares her fear: "They are deadly... It could have overdosed me. I have told Dexcom a few times they are going to kill someone."
The G7 Controversy
The accuracy of Dexcom's new G7 CGM, which recently received government subsidy, is a major point of contention. US regulators have warned Dexcom about relying on data from the G6 to determine the G7's accuracy and the use of a new, unapproved component in sensors that internal testing showed to be less accurate. The Food and Drug Administration's warning letter highlights the higher risks for users who rely on these sensors for diabetes treatment decisions.
Dr. Ng from the Australian Diabetes Educators Association expresses concern: "If I had the choice, I wouldn't go with the G7."
CGMs and Smartphones: A Dangerous Connection
The link between CGMs and smartphones introduces a new vulnerability. The TGA and Dexcom have issued multiple product corrections for app issues, including delays, alarm failures, and silent loss of connection. Abbott's FreeStyle app also experienced a similar issue in 2023, causing silent sensor disconnection on some Android phones.
Antonia Watson, a Melbourne resident, shares her experience with connection issues and inaccurate readings from the FreeStyle Libre 2. She questions the impact of inaccurate CGM readings on people's health: "How many people are treating themselves for lows and highs that don't exist?"
The Daylesford Tragedy and Bluetooth Alarms
The fatal car crash in Daylesford, Victoria, involving William Swale, a man with type 1 diabetes, has brought the issue of CGM-Bluetooth connections to the forefront. Swale's Abbott FreeStyle Libre 2 CGM sent multiple low-blood-sugar alarms before the crash, but he claims he never heard them.
Following the crash, Swale's doctor pointed him to a US regulator's warning about car Bluetooth muting CGM alarms, a warning that the Australian TGA had not passed on to patients. The TGA's decision not to disseminate this critical information has come under scrutiny.
Regulatory Classification and New Sensors
Amidst these concerns, the TGA lowered the regulatory classification of CGMs from high to medium-risk devices in 2024. This move has alarmed some diabetes experts, who are witnessing the influx of new sensors with varying scientific evidence onto the market.
Associate Professor Neale Cohen warns: "There are many, many more coming onto the market that are really not reliable." A coalition of diabetes expert groups has released guidance on minimum standards for CGMs, which some devices, like MiniMed's Guardian CGMs, fail to meet.
Conclusion: A Call for Action
The story of Tye Cummins and others like him highlights the urgent need for improved regulations, transparency, and patient education surrounding diabetes management devices. While technological advancements offer hope and convenience, they must be accompanied by rigorous standards to ensure patient safety. The balance between innovation and protection is delicate, and it is crucial that we get it right.
